Synthesis and Anti-Helicobacter pylori Properties of NO-Donor/ Metronidazole Hybrids and Related Compounds

Drug Development Research

Volumn 60, Issue 3, 2003, Pages 225-239

  Bertinaria, Massimo ^a   Galli, Ubaldina ^b   Sorba, Giovanni ^b   Fruttero, Roberta ^a   Gasco, Alberto ^a   Brenciaglia, Maria Immacolata ^c   Scaltrito, Maria Maddalena ^d   Dubini, Francesco ^d  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

Author keywords

Anti Helicobacter pylori agents; Metronidazole; NO donors

Indexed keywords

1 [2 (2,3 BIS NITROOXYPROPOXY)ETHYL] 2 METHYL 5 NITRO 1H IMIDAZOLE; 1 [2 (ALLYLOXY)ETHYL] 2 METHYL 5 NITRO 1H IMIDAZOLE; 2 (2 METHYL 5 NITRO 1H IMIDAZOL 1 YL)ETHANAMINE HYDROBROMIDE; 2 (2 METHYL 5 NITRO 1H IMIDAZOLYL)ETHYL DERIVATIVE; 2 [2 (2 METHYL 5 NITRO 1H IMIDAZOL 1 YL)ETHOXY]ETHYL NITRATE; 3 [2 (2 METHYL 5 NITRO 1H IMIDAZOL 1 YL)ETHOXY] 4 PHENYLFURAZAN; 3 BENZENESULFONYL 4 [2 (2 METHYL 5 NITRO 1H IMIDAZOL 1 YL)ETHOXY]FURAZAN; 3 BENZENESULFONYL 4 [2 (2 METHYL 5 NITRO 1H IMIDAZOL 1 YL)ETHOXY]FUROXAN; 4 [2 (2 METHYL 5 NITRO 1H IMIDAZOL 1 YL)ETHOXY] 3 PHENYLFUROXAN; FURAZAN DERIVATIVE; METRONIDAZOLE; METRONIDAZOLE DERIVATIVE; NITRIC OXIDE DONOR; NITRIC OXIDE DONOR METRONIDAZOLE HYBRID; OXYGEN; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; ATHEROSCLEROSIS; BACTERIAL STRAIN; CONJUGATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG POTENCY; DRUG SYNTHESIS; HELICOBACTER PYLORI; HYBRID; IN VITRO STUDY; ISCHEMIC HEART DISEASE; NONHUMAN; STOMACH ULCER; STRUCTURE ACTIVITY RELATION;

EID: 0242362780     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/ddr.10284     Document Type: Article

References (44)

1. Alcade E, Manos L, Valls N. 1984. Synthese de derives du nitro-5 imidazole potentiellement actifs en chimiotherapie. J Heterocycl Chem 21:1647-1651.
2. Boschi D, Di Stilo A, Cena C, Lolli M, Fruttero R, Gasco A. 1997. Studies on agents with mixed NO-dependent vasodilating and β-blocking activities. Pharm Res 14:1750-1758.
3. Brunet LR. 2001. Nitric oxide in parasitic infections. Int Immunopharmacol 1:1457-1467.
4. Calvino R, Mortarini V, Gasco A, Sanfilippo A, Ricciardi ML. 1980. Antimicrobial properties of some furazan and furoxan derivatives. Eur J Med Chem Chim Ther 15:485-487.
5. Cerecetto H, Di Maio B, Gonzales M, Risso M, Saenz P, Seoane G, Denicola A, Peluffo G, Quijano C, Olea-Azar C. 1999. 1,2,5-Oxadiazole N-oxide derivatives and related compounds as potential antitrypanosomal drugs: structure-activity relationships. J Med Chem 42:1941-1950.
6. Cole SP, Karitonov VF, Guiney DG. 1999. Effect of Nitric oxide on Helicobacter pylori Morphology. J Infect Dis 180:1713-1717.
7. De Groote MA, Fang FC. 1995. Antimicrobial properties of nitric oxide. Clin Infect Dis 21(suppl 2):S162-S165.
8. Di Stilo A, Visentin S, Cena C, Gasco AM, Ermondi G, Gasco A. 1998. New 1,4-dihydropyridines conjugated to furoxanyl moieties, endowed with both nitric oxide-like and calcium channel antagonist vasodilator activities. J Med Chem 41:5393-5401.
9. Dunstan I, Griffiths JV, Harvey SA. 1965. Nitric esters. Part I. Characterisation of the isomeric glycerol dinitrates. J Chem Soc 1319-1324.
10. Farrar WV. 1964. The 3,4-bisarenesulfonylfuroxans. J Chem Soc 904-906.
11. Farthing MJG, Patchett SE. (editors) 1998. Helicobacter infection. Br Med Bull 54:1-258.
12. Feelish M, Stamler JS. 1996. Donor of nitrogen oxides. In: Feelish M, Stamler JS, editors. Methods in nitric oxide research. Chichester: John Wiley and Sons. p 71-115.
13. Fruttero R, Sorba G, Ermondi G, Lolli M, Gasco A. 1997. Unsymetrically substituted furoxans. XVII. Structural investigations in benzenesulfonylfuroxan derivatives and related compounds. Farmaco 52:405-410.
14. Fruttero B, Caron G, Fornatto E, Boschi D, Ermondi G, Gasco A, Carrupt PA, Testa B. 1998. Mechanism of liposomes/water partitioning of (p-methylbenzyl)alkylamines. Pharm Res 15:1407-1413.
15. Gasco A, Boulton AJ. 1981. Furoxans and benzofuroxans. Adv Heterocyclic Chem 29:251-340.
16. Hay MP, Wilson RW, Moselen JW, Palmer BD, Denny WA. 1994. Hypoxia-selective antitumor agents 8. Bis(nitroimidazolyl)alkane-carboxamides: a new class of hypoxia-selective cytotoxins and hypoxic cell radiosensitisers. J Med Chem 37:381-391.
17. Jenks PJ, Edwards DI. 2002. Metronidazole resistance in Helicobacter Pylori. Int J Antimicrob Ag 19:1-7.
18. Kajfez F, Sunjic V, Kolbah D, Fajdiga T, Oklobdzija M. 1968. 1-Substitution in 2-methyl-4(5)-nitroimidazole. I. Synthesis of compounds with potential antitrichomonas activity. J Med Chem 11:167-169.
19. Kawashima Y, Ikemoto T, Horiguchi A, Hayashi M, Matsumoto K, Kawarasaki K, Yamazaki R, Okuyama S, Hatayama K. 1993. Synthesis and pharmacological evaluation of (nitrooxy)alkyl apovincaminates. J Med Chem 36:815-819.
20. Kenley RA, Bedford CD, Dailey OD, Howd RA, Miller A. 1984. Nonquaternary cholinesterase reactivators. 2. α-Heteroaromatic aldoximes and thiohydroximates as reactivators of ethyl methyl phosphonyl-acetylcholinesterase in vitro. J Med Chem 27: 1201-1211.
21. Kovacic P, Becvar L. 2000. Mode of action of anti-infective agents: focus on oxidative stress and electron transfer. Curr Pharm Des 6:143-167.
22. Loscalzo J, Vita AJ. 2000. Nitric oxide and the cardiovascular system. Totowa, New Jersey: Humana Press. 601 p.
23. Marcinkiewicz J. 1997. Nitric oxide and antimicrobial activity of reactive oxygen intermediates. Immunopharmacology 37:35-41.
24. 13C NMR assignment of structure. Tetrahedron 39:3797-3800.
25. Monge A, Lopez de Cerain A, Ezpeleta O, Cerecetto H, Dias E., Di Maio R, Gonzales M, Onetto S, Seoane G, Suescun L, Mariezcurrena R. 1998a. 1,2,5-Oxadiazole N-oxide derivatives as hypoxia-selective cytotoxins: structure-activity relationships. Pharmazie 53:758-764.
26. Monge A, Lopez de Cerain A, Ezpeleta O, Cerecetto H, Dias E., Di Maio R, Gonzales M, Onetto S, Seoane G, Suescun L, Mariezcurrena R. 1998b. Synthesis and biological evaluation of 1,2,5-oxadiazole N-oxide derivatives as hypoxia-selective cytotoxins. Pharmazie 53:698-702.
27. Nash BW, Newberry RA, Pickles R, Warburton WK. 1969. Synthesis of some disubstituted 1,2,4-oxadiazoles and furazans. J Chem Soc 19:2794-2799.
28. National Committee for Clinical Laboratory Standard. 2000. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; fifth edition. Approved Standard M7-A5. Wayne, Pennsylvania: NCCLS.
29. Pakodi F, Abdel-Salam OME, Debreceni A, Mozsik G. 2000. Helicobacter pylori. One bacterium and a broad spectrum of human disease: an overview. J Physiol (Paris) 94:139-152.
30. Parsonnet J, Friedman GD, Vandersteen DP, Chang Y, Vogelman JH, Orentreich N, Sibley RK. 1991. Helicobacter pylori infection and a risk of gastric carcinoma. N Engl J Med 325:1127-1131.
31. Persichini T, Colasanti M, Fraziano M, Colizzi V, Ascenzi P, and Lauro GM. 1999. Nitric oxide inhibits HIV-1 replication in human astrocytoma cells. Biochem Biophys Res Commun 254:200-202.
32. Pietroiusti A, Diomedi M, Silvestrini M, Cuoini LM, Luzzi I, Gomez-Miguel MJ, Bergamaschi A, Magrini A, Carrabs T, Vellini M, Galante A. 2002. Cytotoxin-associated gene-A-positive Helicobacter pylori strains are associated with atherosclerotic stroke. Circulation 106:580-584.
33. Pollet P, Gellin S. 1979. Tetronic acids and derivatives; part VI. A convenient synthesis of new 4-oxo-2-phenyl-2H-4,6-dihydrofuro[3,4-d]thiazole and 4-oxo-4,6-dihydrofuro[3,4-c]furazan systems. Synthesis 12:977-979.
34. Pörsti I, Paakkari I. 1995. Nitric oxide-based possibilities for pharmacotherapy. Ann Med 27:407-420.
35. Rockett KA, Awburn MM, Cowden WB, Clark IA. 1991. Killing of Plasmodium falciparum in vitro by nitric oxide derivatives. Infect Immun 59:3280-3283.
36. Rolando B, Cena C, Caron G, Marini E, Grosa G, Fruttero R, Gasco A. 2002. NO-donor 1,4-dihydropyridine analogues of amlodipine, Med Chem Res 11:322-332.
37. Shonafinger K. 1999. Heterocyclic NO-donors. Farmaco 54:316-320.
38. Sorba G, Ermondi G, Fruttero R, Galli U, Gasco A. 1996. Unsymmetrically substituted furoxans. Part 16. Reaction of benzenesulfonyl substituted furoxans with ethanol and ethanthiol in basic medium. J Heterocycl Chem 33:327-334.
39. Sorba G, Medana C, Di Stilo A, Cena C, Galli U, Fruttero R, Gasco A. 1997. Water soluble furoxan derivatives as NO-prodrugs. J Med Chem 40:463-469.
40. Stratton CW, Coudron PE. 1997. A practical approach to the diagnosis and therapy of Helicobacter pylori infection. Antimicrob Infect Dis Newslett 16:81-86.
41. Tracy JW, Webster LT Jr. 2001. Drug used in the chemotherapy of protozoal infections. In: Hardman JG, Limbird LE, Goodman Gilman A. Goodman and Gilman's the pharmacological basis of therapeutics, 10th ed. New York: McGraw-Hill Medical Publishing Division. p 1105-1109.
42. Trend MA, Jorgensen MA, Hazell SL, Mendz GL. 2001. Oxidases and reductases are involved in metronidazole sensitivity in Helicobacter pylori. Int J Biochem Cell B 33:143-153.
43. Wallace JL, Granger DN. 1996. The cellular and molecular basis of gastric mucosal defence. FASEB J 10:731-740.
44. Wang PG, Xian M, Tang X, Wu X, Wen Z, Cai T, Janczuk AJ. 2002. Nitric oxide donors. Chem Rev 102:1091-1134.